BR0308957A - Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação - Google Patents
Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparaçãoInfo
- Publication number
- BR0308957A BR0308957A BR0308957-6A BR0308957A BR0308957A BR 0308957 A BR0308957 A BR 0308957A BR 0308957 A BR0308957 A BR 0308957A BR 0308957 A BR0308957 A BR 0308957A
- Authority
- BR
- Brazil
- Prior art keywords
- inflammation
- compounds
- preparation
- patient
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA O TRATAMENTO DE UMA INFLAMAçãO OU DE UMA DESORDEM ASSOCIADA A UMA INFLAMAçãO EM UM PACIENTE, USO DOS COMPOSTOS E PROCESSO PARA SUA PREPARAçãO". A presente invenção refere-se a novos compostos tendo atividade anti-inflamatória, ao processo para sua preparação e a composições farmacêuticas contendo os mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN327MU2002 | 2002-04-05 | ||
PCT/IN2003/000133 WO2003087062A2 (en) | 2002-04-05 | 2003-04-01 | 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0308957A true BR0308957A (pt) | 2005-02-01 |
Family
ID=29415974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0308957-6A BR0308957A (pt) | 2002-04-05 | 2003-04-01 | Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação |
Country Status (22)
Country | Link |
---|---|
US (1) | US7348342B2 (pt) |
EP (1) | EP1492773B1 (pt) |
JP (1) | JP4541711B2 (pt) |
KR (1) | KR100659283B1 (pt) |
CN (1) | CN100351237C (pt) |
AT (1) | ATE422201T1 (pt) |
AU (1) | AU2003238667B2 (pt) |
BR (1) | BR0308957A (pt) |
CA (1) | CA2480678C (pt) |
CY (1) | CY1108932T1 (pt) |
DE (1) | DE60326069D1 (pt) |
DK (1) | DK1492773T3 (pt) |
EA (1) | EA008303B1 (pt) |
ES (1) | ES2321502T3 (pt) |
HK (1) | HK1075450A1 (pt) |
IL (2) | IL163951A0 (pt) |
MX (1) | MXPA04009463A (pt) |
NO (1) | NO328028B1 (pt) |
PT (1) | PT1492773E (pt) |
SI (1) | SI1492773T1 (pt) |
WO (1) | WO2003087062A2 (pt) |
ZA (1) | ZA200407293B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003238667B2 (en) | 2002-04-05 | 2006-07-20 | Cadila Healthcare Limited | 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation |
NZ540515A (en) * | 2002-12-02 | 2008-01-31 | Astellas Pharma Inc | Pyrazole derivatives useful as COX-I inhibitors |
ES2214130B1 (es) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 2-3'-bipiridinas. |
ES2213485B1 (es) | 2003-02-13 | 2005-12-16 | Almirall Prodesfarma, S.A. | Derivados de la 2-fenilpiran-4-ona. |
CN1809559B (zh) | 2003-04-18 | 2010-06-02 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的吡唑衍生物 |
ITMI20040019A1 (it) * | 2004-01-12 | 2004-04-12 | Univ Bari | Derivati isossazolici e loro impiego come inibitori della ciclossigenasi |
US7432266B2 (en) | 2004-10-15 | 2008-10-07 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
CA2613522A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
US7989450B2 (en) | 2008-01-11 | 2011-08-02 | Universita' Degli Studi Di Bari | Functionalized diarylisoxazoles inhibitors of ciclooxygenase |
US8815881B2 (en) * | 2010-08-09 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
CN103204803A (zh) * | 2012-01-13 | 2013-07-17 | 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 | 用于合成依托考昔的方法 |
CN104926797B (zh) * | 2014-06-10 | 2019-04-16 | 北京元博方医药科技有限公司 | 呋喃酮衍生物、制备方法及用途 |
WO2016010609A1 (en) | 2014-07-18 | 2016-01-21 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
CN106278970A (zh) * | 2016-08-09 | 2017-01-04 | 孙冉 | 一种二芳基亚砜胺类化合物的合成方法 |
WO2018029117A1 (en) * | 2016-08-10 | 2018-02-15 | Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) | New atr inhibitors for the use in cancer therapy |
CN107721941B (zh) * | 2017-10-10 | 2020-05-22 | 浦拉司科技(上海)有限责任公司 | 一种3-氨基-5-甲基异噁唑的制备方法 |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4036849A (en) * | 1974-05-15 | 1977-07-19 | American Cyanamid Company | 1-(Para-substituted-phenyl)-1H-tetrazoles |
JPS59165090A (ja) * | 1983-03-07 | 1984-09-18 | インタ−ナショナル ビジネス マシ−ンズ コ−ポレ−ション | 文字発生器 |
DE3522230A1 (de) * | 1985-06-21 | 1987-01-02 | Thomae Gmbh Dr K | Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE3621112A1 (de) * | 1986-06-24 | 1988-01-07 | Merck Patent Gmbh | Nichtracemische sulfoxide |
DE10399017I2 (de) * | 1995-02-13 | 2006-04-27 | Searle & Co | Substituierte isoxazole zur behandlung von Entzündung |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5981576A (en) * | 1995-10-13 | 1999-11-09 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
US6020343A (en) * | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
ES2166710B1 (es) * | 2000-04-25 | 2004-10-16 | J. URIACH & CIA, S.A. | Nuevos compuestos heterociclicos con actividad antiinflamatoria. |
US6673818B2 (en) * | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
AU2003238667B2 (en) | 2002-04-05 | 2006-07-20 | Cadila Healthcare Limited | 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation |
-
2003
- 2003-04-01 AU AU2003238667A patent/AU2003238667B2/en not_active Ceased
- 2003-04-01 PT PT03733003T patent/PT1492773E/pt unknown
- 2003-04-01 CN CNB038073528A patent/CN100351237C/zh not_active Expired - Fee Related
- 2003-04-01 ES ES03733003T patent/ES2321502T3/es not_active Expired - Lifetime
- 2003-04-01 BR BR0308957-6A patent/BR0308957A/pt not_active IP Right Cessation
- 2003-04-01 WO PCT/IN2003/000133 patent/WO2003087062A2/en active Application Filing
- 2003-04-01 DK DK03733003T patent/DK1492773T3/da active
- 2003-04-01 JP JP2003584018A patent/JP4541711B2/ja not_active Expired - Fee Related
- 2003-04-01 SI SI200331561T patent/SI1492773T1/sl unknown
- 2003-04-01 MX MXPA04009463A patent/MXPA04009463A/es active IP Right Grant
- 2003-04-01 KR KR1020047015837A patent/KR100659283B1/ko not_active IP Right Cessation
- 2003-04-01 AT AT03733003T patent/ATE422201T1/de active
- 2003-04-01 US US10/509,894 patent/US7348342B2/en not_active Expired - Fee Related
- 2003-04-01 EP EP03733003A patent/EP1492773B1/en not_active Expired - Lifetime
- 2003-04-01 DE DE60326069T patent/DE60326069D1/de not_active Expired - Lifetime
- 2003-04-01 IL IL16395103A patent/IL163951A0/xx unknown
- 2003-04-01 EA EA200401319A patent/EA008303B1/ru not_active IP Right Cessation
- 2003-04-01 CA CA2480678A patent/CA2480678C/en not_active Expired - Fee Related
-
2004
- 2004-04-19 ZA ZA200407293A patent/ZA200407293B/en unknown
- 2004-09-07 IL IL163951A patent/IL163951A/en not_active IP Right Cessation
- 2004-09-10 NO NO20043792A patent/NO328028B1/no not_active IP Right Cessation
-
2005
- 2005-10-27 HK HK05109544A patent/HK1075450A1/xx not_active IP Right Cessation
-
2009
- 2009-03-30 CY CY20091100370T patent/CY1108932T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2003087062A2 (en) | 2003-10-23 |
CA2480678C (en) | 2011-06-14 |
NO20043792L (no) | 2005-01-04 |
US7348342B2 (en) | 2008-03-25 |
MXPA04009463A (es) | 2005-01-25 |
EP1492773B1 (en) | 2009-02-04 |
CN100351237C (zh) | 2007-11-28 |
EP1492773A2 (en) | 2005-01-05 |
IL163951A0 (en) | 2005-12-18 |
CY1108932T1 (el) | 2014-07-02 |
HK1075450A1 (en) | 2005-12-16 |
JP4541711B2 (ja) | 2010-09-08 |
DK1492773T3 (da) | 2009-04-14 |
NO328028B1 (no) | 2009-11-16 |
AU2003238667B2 (en) | 2006-07-20 |
SI1492773T1 (sl) | 2009-06-30 |
CN1642918A (zh) | 2005-07-20 |
KR100659283B1 (ko) | 2006-12-19 |
AU2003238667A1 (en) | 2003-10-27 |
CA2480678A1 (en) | 2003-10-23 |
EA200401319A1 (ru) | 2005-04-28 |
EA008303B1 (ru) | 2007-04-27 |
US20050277678A1 (en) | 2005-12-15 |
DE60326069D1 (de) | 2009-03-19 |
ZA200407293B (en) | 2006-07-26 |
JP2005530728A (ja) | 2005-10-13 |
ES2321502T3 (es) | 2009-06-08 |
KR20040099400A (ko) | 2004-11-26 |
PT1492773E (pt) | 2009-05-07 |
ATE422201T1 (de) | 2009-02-15 |
IL163951A (en) | 2010-11-30 |
WO2003087062A3 (en) | 2003-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0308957A (pt) | Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação | |
BR9812753A (pt) | Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica | |
BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
ATE361084T1 (de) | Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
BR0315580A (pt) | Derivados de metileno uréia | |
BRPI0409227A (pt) | composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto | |
BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
BR9917038A (pt) | Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias | |
ATE432072T1 (de) | Verwendung von adapalen zur behandlung dermatologischer erkrankungen | |
BRPI0418351A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo | |
DE602004032522D1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
BR0309278A (pt) | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto | |
BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
BRPI0114344B8 (pt) | composto retinóide, seu uso, sua composição farmacêutica e seu processo de preparação | |
BRPI0514600A (pt) | métodos para a fabricação de um composto, para a purificação de um composto, para o tratamento de um indivìduo tendo uma condição neoplástica, tendo carcinoma de célula escamosa, e tendo carcinoma de célula basal, para a redução ou prevenção da ocorrência de uma condição neoplástica em um indivìduo, e para a redução de triglicerìdeos no soro em um indivìduo, composto, e, composição farmacêutica | |
BRPI0411176A (pt) | combinação farmacêutica consistindo de modafinil e outra droga | |
ATE191472T1 (de) | Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen | |
ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
ATE353650T1 (de) | Kombinationstherapie zur behandlung von krebs | |
BR0315247A (pt) | Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |